// App-Quantinova.ai

OC 21.2 : Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

Researchers

Presenter

  • M. Laffan

Principal Investigators

  • S. Rangarajan

  • W. Lester

  • E. Symington

  • B. Madan

  • D. Hart

  • M. Li

  • T. Robinson

  • G. Pierce

  • W. Wong

Medical Centers

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

  • BioMarin Pharmaceutical Inc., Novato, United States

  • BioMarin Pharmaceutical Inc., Novato, United States

  • Independent, La Jolla, California, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Hemostatic Solution

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT02576795

Sponsors

  • BioMarin Pharmaceutical Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved